Followers | 183 |
Posts | 25217 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Monday, June 14, 2021 10:38:21 AM
From the company website:
IkT-148009 for Parkinson’s Disease
Our lead small-molecule product candidate, IkT-148009, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that targets underlying disease mechanisms to halt the progression and reverse functional loss of Parkinson’s disease in the brain and the GI complications of Parkinson’s disease. We believe that IkT-148009 is the only disease-modifying drug in development for Parkinson’s disease that is focused on a clinically validated target and that IkT-148009 has the potential to be the first disease-modifying therapy for Parkinson’s disease that blocks a checkpoint on the pathway that drives Parkinson’s disease progression.
ABOUT IKT-148009
First-in-class Therapy to Reverse the Course of Parkinson’s Disease
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in the brain and GI tract in animal models using IkT-148009, we submitted two Investigational New Drug (IND) applications in February, 2019, to begin clinical development in multiple classes of Parkinson’s patients. Clinical development should proceed through 2024.
Recent IKT News
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 08/14/2024 08:25:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:14:00 PM
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:18:33 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/18/2024 09:27:36 PM
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease • GlobeNewswire Inc. • 06/17/2024 12:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 08:20:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:05:30 PM
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs • GlobeNewswire Inc. • 06/05/2024 12:05:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/04/2024 08:11:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/22/2024 12:55:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:55:02 PM
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million • GlobeNewswire Inc. • 05/20/2024 12:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 11:09:42 AM
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 05/16/2024 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:04:56 PM
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement • GlobeNewswire Inc. • 05/15/2024 12:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/15/2024 11:56:55 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/09/2024 06:41:37 PM
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM